RESUMEN
Recently, a guideline has been published by the European Medicines Agency (EMA) on setting safe limits, permitted daily exposures (PDE) [also called acceptable daily exposures (ADE)], for medicines manufactured in multi-product facilities. The ADE provides a safe exposure limit for inadvertent exposure of a drug due to cross-contamination in manufacturing. The ADE determination encompasses a standard risk assessment, requiring an understanding of the toxicological and pharmacological effects, the mechanism of action, drug compound class, and the dose-response as well as the pharmacokinetic properties of the compound. While the ADE concept has broad application in pharmaceutical safety there are also nuances and specific challenges associated with some toxicological endpoints or drug product categories. In this manuscript we discuss considerations for setting ADEs when the following specific adverse health endpoints may constitute the critical effect: genotoxicity, developmental and reproductive toxicity (DART), and immune system modulation (immunostimulation or immunosuppression), and for specific drug classes, including antibody drug conjugates (ADCs), emerging medicinal therapeutic compounds, and compounds with limited datasets. These are challenging toxicological scenarios that require a careful evaluation of all of the available information in order to establish a health-based safe level.
Asunto(s)
Industria Farmacéutica , Nivel sin Efectos Adversos Observados , Exposición Profesional/prevención & control , Salud Laboral , Preparaciones Farmacéuticas , Proteínas/efectos adversos , Pruebas de Toxicidad/métodos , Animales , Relación Dosis-Respuesta a Droga , Contaminación de Medicamentos/prevención & control , Hipersensibilidad a las Drogas/inmunología , Hipersensibilidad a las Drogas/prevención & control , Industria Farmacéutica/legislación & jurisprudencia , Industria Farmacéutica/normas , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/inmunología , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/prevención & control , Guías como Asunto , Política de Salud , Humanos , Pruebas de Mutagenicidad , Exposición Profesional/efectos adversos , Exposición Profesional/legislación & jurisprudencia , Exposición Profesional/normas , Salud Laboral/legislación & jurisprudencia , Salud Laboral/normas , Preparaciones Farmacéuticas/clasificación , Preparaciones Farmacéuticas/normas , Farmacocinética , Formulación de Políticas , Proteínas/clasificación , Proteínas/normas , Medición de Riesgo , Pruebas de Toxicidad/normas , ToxicocinéticaRESUMEN
The Acceptable Daily Exposure (ADE) derived for pharmaceutical manufacturing is a health-based limit used to ensure that medicines produced in multi-product facilities are safe and are used to validate quality processes. Core to ADE derivation is selecting appropriate point(s) of departure (PoD), i.e., the starting dose of a given dataset that is used in the calculation of the ADE. Selecting the PoD involves (1) data collection and hazard characterization, (2) identification of "critical effects", and (3) a dose-response assessment including the determination of the no-observed-adverse-effect-level (NOAEL) or lowest-observed-adverse-effect-level (LOAEL), or calculating a benchmark dose (BMD) level. Compared to other classes of chemicals, active pharmaceutical ingredients (APIs) are well-characterized and have unique, rich datasets that must be considered when selecting the PoD. Dataset considerations for an API include therapeutic/pharmacological effects, particularities of APIs for different indications and routes of administration, data gaps during drug development, and sensitive subpopulations. Thus, the PoD analysis must be performed by a qualified toxicologist or other expert who also understands the complexities of pharmaceutical datasets. In addition, as the pharmaceutical industry continues to evolve new therapeutic principles, the science behind PoD selection must also evolve to ensure state-of-the-science practices and resulting ADEs.
Asunto(s)
Industria Farmacéutica , Nivel sin Efectos Adversos Observados , Exposición Profesional/prevención & control , Salud Laboral , Preparaciones Farmacéuticas , Animales , Benchmarking , Relación Dosis-Respuesta a Droga , Industria Farmacéutica/legislación & jurisprudencia , Industria Farmacéutica/normas , Guías como Asunto , Política de Salud , Humanos , Exposición Profesional/efectos adversos , Exposición Profesional/legislación & jurisprudencia , Exposición Profesional/normas , Salud Laboral/legislación & jurisprudencia , Salud Laboral/normas , Preparaciones Farmacéuticas/clasificación , Preparaciones Farmacéuticas/normas , Farmacocinética , Formulación de Políticas , Medición de Riesgo , Pruebas de ToxicidadRESUMEN
Historically, pharmaceutical industry regulatory guidelines have assigned certain active pharmaceutical ingredients (APIs) to various categories of concern, such as "cytotoxic", "hormones", and "steroids". These categories have been used to identify APIs requiring segregation or dedication in order to prevent cross-contamination and protect the quality and safety of drug products. Since these terms were never defined by regulatory authorities, and many novel pharmacological mechanisms challenge these categories, there is a recognized need to modify the historical use of these terms. The application of a risk-based approach using a health-based limit, such as an acceptable daily exposure (ADE), is more appropriate for the development of a Quality Risk Management Program (QRMP) than the use of categories of concern. The toxicological and pharmacological characteristics of these categories are discussed to help identify and prioritize compounds requiring special attention. Controlling airborne concentrations and the contamination of product contact surfaces in accordance with values derived from quantitative risk assessments can prevent adverse effects in workers and patients, regardless of specific categorical designations to which these APIs have been assigned. The authors acknowledge the movement away from placing compounds into categories and, while not yet universal, the importance of basing QRMPs on compound-specific ADEs and risk assessments. Based on the results of a risk assessment, segregation and dedication may also be required for some compounds to prevent cross contamination during manufacture of APIs.
Asunto(s)
Contaminación de Medicamentos/prevención & control , Industria Farmacéutica , Nivel sin Efectos Adversos Observados , Exposición Profesional/prevención & control , Salud Laboral , Preparaciones Farmacéuticas , Animales , Industria Farmacéutica/historia , Industria Farmacéutica/legislación & jurisprudencia , Industria Farmacéutica/normas , Guías como Asunto , Política de Salud , Historia del Siglo XXI , Humanos , Exposición Profesional/efectos adversos , Exposición Profesional/legislación & jurisprudencia , Exposición Profesional/normas , Salud Laboral/historia , Salud Laboral/legislación & jurisprudencia , Salud Laboral/normas , Preparaciones Farmacéuticas/clasificación , Preparaciones Farmacéuticas/historia , Preparaciones Farmacéuticas/normas , Formulación de Políticas , Control de Calidad , Medición de Riesgo , Pruebas de ToxicidadRESUMEN
Cross-contamination in multi-product pharmaceutical manufacturing facilities can impact both product safety and quality. This issue has been recognized by regulators and industry for some time, leading to publication of a number of continually evolving guidelines. This manuscript provides a historical overview of the regulatory framework for managing cross-contamination in multi-product facilities to provide context for current approaches. Early guidelines focused on the types of pharmaceuticals for which dedicated facilities and control systems were needed, and stated the requirements for cleaning validation. More recent guidelines have promoted the idea of using Acceptable Daily Exposures (ADEs) to establish cleaning limits for actives and other potentially hazardous substances. The ADE approach is considered superior to previous methods for setting cleaning limits such as using a predetermined general limit (e.g., 10 ppm or a fraction of the median lethal dose (LD50) or therapeutic dose). The ADEs can be used to drive the cleaning process and as part of the overall assessment of whether dedicated production facilities are required. While great strides have been made in using the ADE approach, work remains to update good manufacturing practices (GMPs) to ensure that the approaches are clear, consistent with the state-of-the-science, and broadly applicable yet flexible enough for adaptation to unique products and situations.
Asunto(s)
Contaminación de Medicamentos/prevención & control , Industria Farmacéutica , Nivel sin Efectos Adversos Observados , Exposición Profesional/prevención & control , Salud Laboral , Preparaciones Farmacéuticas/análisis , Animales , Difusión de Innovaciones , Contaminación de Medicamentos/legislación & jurisprudencia , Industria Farmacéutica/historia , Industria Farmacéutica/legislación & jurisprudencia , Industria Farmacéutica/normas , Industria Farmacéutica/tendencias , Predicción , Guías como Asunto , Política de Salud , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Exposición Profesional/efectos adversos , Exposición Profesional/legislación & jurisprudencia , Exposición Profesional/normas , Salud Laboral/historia , Salud Laboral/legislación & jurisprudencia , Salud Laboral/normas , Salud Laboral/tendencias , Preparaciones Farmacéuticas/clasificación , Preparaciones Farmacéuticas/normas , Formulación de Políticas , Control de Calidad , Medición de Riesgo , Pruebas de ToxicidadRESUMEN
Acceptable daily exposures (ADEs) are established to determine the quantity of one drug substance that can contaminate another drug product without causing harm to the patient. An important part in setting an ADE for a drug substance, after identification of the unwanted critical effect(s) of the compound (see Bercu et al., 2016, this issue), is the determination of an appropriate overall margin of safety that is need to be maintained below the dose causing a certain critical effect (i.e., the point of departure or PoD). The overall margin of safety used to protect the general patient population from critical effects is derived as the product (i.e., composite adjustment factor) of various individual factors that account for variability and uncertainty in extrapolating from the PoD to an ADE. These factors address the considerations of interindividual variability, interspecies extrapolation, LOAEL-to-NOAEL extrapolation, exposure duration adjustment, effect severity, and database completeness. The factors are considered individually, but are not necessarily independent and their interdependence should be identified, with subsequent adjustment to the composite factor, as appropriate. It is important to identify all sources of variability and uncertainty pertinent to the derivation of the ADE and ensure each is considered in the assessment, at least by one of the adjustment factors. This manuscript highlights the basis for and selection of factors that address variability and uncertainty as used in the guidance documents on setting ADEs or other related health-based limits.
Asunto(s)
Industria Farmacéutica , Nivel sin Efectos Adversos Observados , Exposición Profesional/prevención & control , Salud Laboral , Preparaciones Farmacéuticas , Animales , Relación Dosis-Respuesta a Droga , Industria Farmacéutica/legislación & jurisprudencia , Industria Farmacéutica/normas , Guías como Asunto , Política de Salud , Humanos , Modelos Biológicos , Exposición Profesional/efectos adversos , Exposición Profesional/legislación & jurisprudencia , Exposición Profesional/normas , Salud Laboral/legislación & jurisprudencia , Salud Laboral/normas , Preparaciones Farmacéuticas/clasificación , Preparaciones Farmacéuticas/normas , Formulación de Políticas , Medición de Riesgo , Especificidad de la Especie , Pruebas de ToxicidadRESUMEN
This manuscript discusses the different historical and more recent default approaches that have been used to derive an acceptable daily exposure (ADE). While it is preferable to derive a health-based ADE based on a complete nonclinical and clinical data package, this is not always possible. For instance, for drug candidates in early development there may be no or limited nonclinical or clinical trial data. Alternative approaches that can support decision making with less complete data packages represent a variety of methods that rely on default assumptions or data inputs where chemical-specific data on health effects are lacking. A variety of default approaches are used including those based on certain toxicity estimates, a fraction of the therapeutic dose, cleaning-based limits, the threshold of toxicological concern (TTC), and application of hazard banding tools such as occupational exposure banding (OEB). Each of these default approaches is discussed in this manuscript, including their derivation, application, strengths, and limitations. In order to ensure patient safety when faced with toxicological and clinical data-gaps, default ADE methods should be purposefully as or more protective than ADEs derived from full data packages. Reliance on the subset of default approaches (e.g., TTC or OEB) that are based on toxicological data is preferred over other methods for establishing ADEs in early development while toxicology and clinical data are still being collected.
Asunto(s)
Industria Farmacéutica , Nivel sin Efectos Adversos Observados , Exposición Profesional/prevención & control , Salud Laboral , Preparaciones Farmacéuticas , Pruebas de Toxicidad/métodos , Animales , Relación Dosis-Respuesta a Droga , Industria Farmacéutica/historia , Industria Farmacéutica/legislación & jurisprudencia , Industria Farmacéutica/normas , Guías como Asunto , Política de Salud , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Dosificación Letal Mediana , Exposición Profesional/efectos adversos , Exposición Profesional/legislación & jurisprudencia , Exposición Profesional/normas , Salud Laboral/historia , Salud Laboral/legislación & jurisprudencia , Salud Laboral/normas , Preparaciones Farmacéuticas/clasificación , Preparaciones Farmacéuticas/historia , Preparaciones Farmacéuticas/normas , Formulación de Políticas , Reproducibilidad de los Resultados , Medición de Riesgo , Pruebas de Toxicidad/historia , Pruebas de Toxicidad/normasRESUMEN
The purpose of this paper is to describe the use of toxicokinetic (TK) and toxicodynamic (TD) data in setting acceptable daily exposure (ADE) values and occupational exposure limits (OELs). Use of TK data can provide a more robust exposure limit based on a rigorous evaluation of systemic internal dose. Bioavailability data assist in extrapolating across different routes of exposure to be protective for route-based differences of exposure. Bioaccumulation data enable extrapolation to chronic exposures when the point of departure (PoD) is from a short-term critical study. Applied in the context of chemical-specific adjustment factors (CSAFs), TK data partially replace traditional default adjustment factors for interspecies extrapolation (extrapolation from studies conducted in animals to humans) and intraspecies variability (to account for human population variability). Default adjustments of 10-fold each for interspecies and intraspecies extrapolation are recommended in several guidelines, although some organization recommend other values. Such default factors may overestimate variability for many APIs, while not being sufficiently protective for variability with other APIs. For this reason, the use of chemical specific TK and TD data are preferred. Making full use of existing TK and TD data reduces underlying uncertainties, increases transparency, and ensures that resulting ADEs reflect the best available science.
Asunto(s)
Industria Farmacéutica , Nivel sin Efectos Adversos Observados , Exposición Profesional/prevención & control , Salud Laboral , Preparaciones Farmacéuticas , Toxicocinética , Animales , Área Bajo la Curva , Industria Farmacéutica/legislación & jurisprudencia , Industria Farmacéutica/normas , Guías como Asunto , Semivida , Política de Salud , Humanos , Tasa de Depuración Metabólica , Modelos Biológicos , Exposición Profesional/efectos adversos , Exposición Profesional/legislación & jurisprudencia , Exposición Profesional/normas , Salud Laboral/legislación & jurisprudencia , Salud Laboral/normas , Preparaciones Farmacéuticas/clasificación , Preparaciones Farmacéuticas/normas , Formulación de Políticas , Medición de Riesgo , Especificidad de la Especie , Pruebas de ToxicidadRESUMEN
This manuscript centers on communication with key stakeholders of the concepts and program goals involved in the application of health-based pharmaceutical cleaning limits. Implementation of health-based cleaning limits, as distinct from other standards such as 1/1000th of the lowest clinical dose, is a concept recently introduced into regulatory domains. While there is a great deal of technical detail in the written framework underpinning the use of Acceptable Daily Exposures (ADEs) in cleaning (for example ISPE, 2010; Sargent et al., 2013), little is available to explain how to practically create a program which meets regulatory needs while also fulfilling good manufacturing practice (GMP) and other expectations. The lack of a harmonized approach for program implementation and communication across stakeholders can ultimately foster inappropriate application of these concepts. Thus, this period in time (2014-2017) could be considered transitional with respect to influencing best practice related to establishing health-based cleaning limits. Suggestions offered in this manuscript are intended to encourage full and accurate communication regarding both scientific and administrative elements of health-based ADE values used in pharmaceutical cleaning practice. This is a large and complex effort that requires: 1) clearly explaining key terms and definitions, 2) identification of stakeholders, 3) assessment of stakeholders' subject matter knowledge, 4) formulation of key messages fit to stakeholder needs, 5) identification of effective and timely means for communication, and 6) allocation of time, energy, and motivation for initiating and carrying through with communications.
Asunto(s)
Industria Farmacéutica , Comunicación Interdisciplinaria , Nivel sin Efectos Adversos Observados , Exposición Profesional/prevención & control , Salud Laboral , Preparaciones Farmacéuticas , Animales , Conducta Cooperativa , Industria Farmacéutica/legislación & jurisprudencia , Industria Farmacéutica/normas , Guías como Asunto , Política de Salud , Humanos , Exposición Profesional/efectos adversos , Exposición Profesional/legislación & jurisprudencia , Exposición Profesional/normas , Salud Laboral/legislación & jurisprudencia , Salud Laboral/normas , Objetivos Organizacionales , Preparaciones Farmacéuticas/clasificación , Preparaciones Farmacéuticas/normas , Formulación de Políticas , Desarrollo de Programa , Medición de Riesgo , Pruebas de ToxicidadRESUMEN
A European Union (EU) regulatory guideline came into effect for all new pharmaceutical products on June 1st, 2015, and for all existing pharmaceutical products on December 1st, 2015. This guideline centers around the use of the Acceptable Daily Exposure (ADE) [synonymous with the Permitted Daily Exposure (PDE)] and operational considerations associated with implementation are outlined here. The EU guidance states that all active pharmaceutical ingredients (API) require an ADE; however, other substances such as starting materials, process intermediates, and cleaning agents may benefit from an ADE. Problems in setting ADEs for these additional substances typically relate to toxicological data limitations precluding the ability to establish a formal ADE. Established methodologies such as occupational exposure limits or bands (OELs or OEBs) and the threshold of toxicological concern (TTC) can be used or adjusted for use as interim ADEs when only limited data are available and until a more formal ADE can be established. Once formal ADEs are derived, it is important that the documents are routinely updated and that these updates are communicated to appropriate stakeholders. Another key operational consideration related to data-poor substances includes the use of maximum daily dose (MDD) in setting cross-contamination limits. The MDD is an important part of the maximum allowable/safe concentration (MAC/MSC) calculation and there are important considerations for its use and definition. Finally, other considerations discussed include operational aspects of setting ADEs for pediatrics, considerations for large molecules, and risk management in shared facilities.
Asunto(s)
Industria Farmacéutica , Nivel sin Efectos Adversos Observados , Exposición Profesional/prevención & control , Salud Laboral , Preparaciones Farmacéuticas , Animales , Relación Dosis-Respuesta a Droga , Industria Farmacéutica/legislación & jurisprudencia , Industria Farmacéutica/normas , Guías como Asunto , Política de Salud , Humanos , Exposición Profesional/efectos adversos , Exposición Profesional/legislación & jurisprudencia , Exposición Profesional/normas , Salud Laboral/legislación & jurisprudencia , Salud Laboral/normas , Preparaciones Farmacéuticas/clasificación , Preparaciones Farmacéuticas/normas , Formulación de Políticas , Medición de Riesgo , Pruebas de ToxicidadAsunto(s)
Industria Farmacéutica , Nivel sin Efectos Adversos Observados , Exposición Profesional/prevención & control , Salud Laboral , Preparaciones Farmacéuticas , Animales , Industria Farmacéutica/legislación & jurisprudencia , Industria Farmacéutica/normas , Guías como Asunto , Política de Salud , Humanos , Exposición Profesional/efectos adversos , Exposición Profesional/legislación & jurisprudencia , Exposición Profesional/normas , Salud Laboral/legislación & jurisprudencia , Salud Laboral/normas , Preparaciones Farmacéuticas/clasificación , Preparaciones Farmacéuticas/normas , Formulación de Políticas , Medición de Riesgo , Pruebas de ToxicidadRESUMEN
Occupational exposure limits (OELs) for active pharmaceutical ingredients have traditionally been established using no-observed-adverse-effect levels derived from clinical studies employing po and iv routes of administration and by applying default uncertainty factors or chemical-specific adjustment factors. However, exposure by the inhalation or dermal route is more relevant in terms of occupational safety. In this investigation, to explore new methods for route-to-route extrapolation, the bioavailability of MK-0679, a leukotriene D(4) receptor antagonist, was compared following iv, po, intranasal (in), or intratracheal (it) administration. The relative bioavailability of MK-0679 was iv congruent with it > po congruent with in. Bioavailability correction factors (BCFs) of 2.0 and 0.6 were derived from these data to adjust a hypothetical OEL of 0.1 mg/m(3) for MK-0679 with particle sizes of 10 and 50 mum, respectively. These BCFs were used to adjust the OEL established using po clinical data, to reflect the differences in bioavailability following deposition in different regions of the respiratory tract. To further investigate how bioavailability data could be used in setting OELs, a preliminary pharmacokinetic (PK) model was developed to describe the time course of plasma concentrations using the data from the route comparison study. An inhalation study was then performed to test the validity of using either empirical data or modeling approaches to derive BCFs when setting OELs. These investigations demonstrated how the use of route-specific PK data could reduce some of the uncertainties associated with route-to-route extrapolation and allow for improved precision and quantitative adjustments when establishing OELs. Further investigations are needed to better understand the factors responsible for differences in systemic uptake following deposition in different regions of the respiratory tract and how these can be generalized across different classes of soluble compounds.